Adicet Bio Announces 1-for-16 Reverse Stock Split to Maintain Listing Compliance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 26 2025
0mins
Source: Benzinga
- Reverse Stock Split Plan: Adicet Bio announced a 1-for-16 reverse stock split effective December 30, which will reduce the outstanding shares from approximately 153.3 million to about 9.6 million, enabling the company to regain compliance with the minimum bid price requirement for continued listing.
- Shareholder Approval: The plan was approved by shareholders at a special meeting last week, indicating support for the company's governance and future direction, although this move may lead to short-term stock price volatility.
- Stock Price Impact: Following the announcement, Adicet Bio shares fell by 5.78%, trading at $0.49, reflecting market caution regarding the measure and potentially impacting investor confidence.
- Incentive Plan Adjustments: Proportional adjustments will be made to shares included in the company's equity incentive plans, with no fractional shares issued, aimed at maintaining the effectiveness of employee incentives while ensuring stability in the company's capital structure.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ACET
Wall Street analysts forecast ACET stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACET is 10.67 USD with a low forecast of 5.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.450
Low
5.00
Averages
10.67
High
18.00
Current: 8.450
Low
5.00
Averages
10.67
High
18.00
About ACET
Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Reports Positive Phase 2b Results for Lupus Drug Nipocalimab, Plans Phase 3 Trial
- Positive Study Results: Johnson & Johnson's JASMINE study involving 228 systemic lupus erythematosus patients met its primary endpoint, demonstrating statistically significant improvement in patient response rates at Week 24 compared to placebo, marking the first positive results for an investigational FcRn blocker in this indication.
- Safety Profile Consistent: Nipocalimab exhibited a safety and tolerability profile consistent with previous Phase 2 studies, with no new safety signals identified, thereby establishing a solid foundation for further clinical development.
- Significant Market Potential: With systemic lupus erythematosus affecting an estimated 3 to 5 million people globally, including 450,000 in the U.S., the positive study results could provide a strong competitive advantage for Johnson & Johnson in this market.
- Clear Next Steps: Following the positive Phase 2 results, Johnson & Johnson plans to initiate a Phase 3 program for Nipocalimab, aiming to further validate its therapeutic potential in systemic lupus erythematosus, which could drive future revenue growth for the company.
Continue Reading
Adicet Bio Announces 1-for-16 Reverse Stock Split to Maintain Listing Compliance
- Reverse Stock Split Plan: Adicet Bio announced a 1-for-16 reverse stock split effective December 30, which will reduce the outstanding shares from approximately 153.3 million to about 9.6 million, enabling the company to regain compliance with the minimum bid price requirement for continued listing.
- Shareholder Approval: The plan was approved by shareholders at a special meeting last week, indicating support for the company's governance and future direction, although this move may lead to short-term stock price volatility.
- Stock Price Impact: Following the announcement, Adicet Bio shares fell by 5.78%, trading at $0.49, reflecting market caution regarding the measure and potentially impacting investor confidence.
- Incentive Plan Adjustments: Proportional adjustments will be made to shares included in the company's equity incentive plans, with no fractional shares issued, aimed at maintaining the effectiveness of employee incentives while ensuring stability in the company's capital structure.
Continue Reading